Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zafirlukast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 known ✓ | Q9Y271 | 5/20 | 1.00 |
| ▸ | PLA2G4A | P47712 | 5/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 4/20 | 1.00 |
| ▸ | PPARG | P37231 | 4/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | PTGES | O14684 | 1/20 | 1.00 |
| ▸ | XPO1 | O14980 | 1/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zafirlukast SCHEMBL4175 | 1.00 | PLA2G4A (1.00) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL29861631 | 1.00 | PLA2G4A (1.00) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL29372773 | 1.00 | PLA2G4A (1.00) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL30885065 | 1.00 | PLA2G4A (1.00) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL6765680 | 0.99 | PLA2G4A (0.99) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL4586973 | 0.99 | PLA2G4A (0.99) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL8951202 | 0.99 | PLA2G4A (0.99) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL6381072 | 0.99 | PLA2G4A (0.99) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL6378803 | 0.99 | PLA2G4A (0.99) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL6715413 | 0.99 | PLA2G4A (0.97) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585109-A2 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ORGAN INJURY AND/OR DYSFUNCTION | The General Hospital Corporation (US) | 2013-05-01 | — | — | EP | claimed |
| WO-2011163308-A2 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ORGAN INJURY AND/OR DYSFUNCTION | THE GENERAL HOSPITAL CORPORATION (US) | 2011-12-29 | — | — | WO | claimed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-20170128475-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ORGAN INJURY AND/OR DYSFUNCTION | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-11 | — | — | US | disclosed |
| EP-2585109-B1 | COMPOSITIONS FOR USE IN TREATING DRUG-INDUCED LIVER TOXICITY OR LIVER FAILURE | MASSACHUSETTS GEN HOSPITAL (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20140148413-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ORGAN INJURY AND/OR DYSFUNCTION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-05-29 | — | — | US | disclosed |
| EP-2585109-A2 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ORGAN INJURY AND/OR DYSFUNCTION | The General Hospital Corporation (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2011163308-A2 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ORGAN INJURY AND/OR DYSFUNCTION | THE GENERAL HOSPITAL CORPORATION (US) | 2011-12-29 | — | — | WO | disclosed |
| EP-1373258-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| EP-1355884-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1355907-A1 | THIAZOLYL-, OXAZOLYL-, PYRROLYL-, AND IMIDAZOLYL-ACID AMIDE DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1252157-A1 | PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-1252158-A1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2002060898-A1 | THIAZOLYL-, OXAZOLYL-, PYRROLYL-, AND IMIDAZOLYL-ACID AMIDE DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| WO-2002060875-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| WO-2002060896-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| WO-2001057025-A1 | PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001057036-A1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | disclosed |